QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:ONVO

Organovo (ONVO) Stock Forecast, Price & News

$2.56
+0.01 (+0.39%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.51
$2.59
50-Day Range
$2.32
$4.08
52-Week Range
$2.24
$11.25
Volume
12,345 shs
Average Volume
41,994 shs
Market Capitalization
$22.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.63
30 days | 90 days | 365 days | Advanced Chart
Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Organovo logo

About Organovo

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Headlines

Organovo (NASDAQ:ONVO) Now Covered by StockNews.com
Organovo Holdings Inc (ONVO)
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.20 million
Book Value
$5.51 per share

Profitability

Net Income
$-16.83 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,532,000
Market Cap
$22.29 million
Optionable
Optionable

Company Calendar

Last Earnings
8/08/2019
Today
5/16/2022
Next Earnings (Estimated)
6/21/2022
Fiscal Year End
3/31/2023

MarketRank

Overall MarketRank

0.98 out of 5 stars

Medical Sector

1269th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

193rd out of 209 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Organovo (NASDAQ:ONVO) Frequently Asked Questions

Is Organovo a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Organovo stock.
View analyst ratings for Organovo
or view top-rated stocks.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Tuesday, June 21st 2022.
View our earnings forecast for Organovo
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.77 million.
View Organovo's earnings history
.

When did Organovo's stock split? How did Organovo's stock split work?

Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

Who are Organovo's key executives?
Organovo's management team includes the following people:
  • Mr. Keith E. Murphy, Exec. Chairman & Principal Exec. Officer (Age 50, Pay $397.18k)
  • Dr. Jeffrey N. Miner, Chief Scientific Officer (Age 60, Pay $221.09k)
  • Mr. Thomas Einar Jurgensen J.D., MS, Gen. Counsel & Corp. Sec. (Age 65, Pay $264.86k)
  • Mr. Thomas P. Hess CPA, MBA, Chief Financial Officer (Age 58)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
  • Dr. Curtis M. Tyree Ph.D., Sr. VP of Strategy & Bus. Devel.
What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (3.52%), Vanguard Group Inc. (3.10%), Renaissance Technologies LLC (1.82%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).
View institutional ownership trends for Organovo
.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, ARK Investment Management LLC, and Simplex Trading LLC.
View insider buying and selling activity for Organovo
or view top insider-selling stocks.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $2.56.

How much money does Organovo make?

Organovo has a market capitalization of $22.29 million and generates $2.20 million in revenue each year. The medical research company earns $-16.83 million in net income (profit) each year or ($1.390010) on an earnings per share basis.

How many employees does Organovo have?

Organovo employs 12 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at (858) 224-1000 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.